



OCT Clinical Completes Enrollment for Phase III Influenza Study

OCT Clinical, one of Eastern Europe's leading CROs, successfully recruits 440 patients to test the drug Ibuklin in treating influenza.

ST. PETERSBURG, RUSSIA, November 25, 2019 /EINPresswire.com/ -- [OCT Clinical Trials](#), a leading [European CRO](#) headquartered in Russia, today announced it has completed enrollment for a phase III study on behalf of Indian pharmaceutical company Dr. Reddy's Laboratories.

OCT successfully enrolled 440 patients — men and women over the age of 18 with acute influenza symptoms — to test the safety and efficacy of the drug Ibuklin. The enrollment target was reached within an impressive seven months, despite seasonal challenges of the indication. With 442 volunteers screened in total, OCT also achieved a low screen failure rate, at just 1%.

"We are pleased with OCT Clinical's ability to meet our recruitment needs within our timeline, especially through the summer months," said Alexander Khaymenov, MD, Ph.D., Head of [Clinical Research](#) at Dr. Reddy's Laboratories' representative office in Russia.

The open, comparative, randomized, multi-center study will run in parallel groups with a treatment period of five days. In this project, OCT Clinical has been responsible for a wide range of activities, including medical writing, regulatory support, project management, pharmacovigilance, monitoring, data management and biostatistics, logistics and writing the final research report.

"OCT is proud to support Dr. Reddy's with our recruitment expertise," said Maxime Stevens, Chief Strategy and Development Officer, OCT Clinical. "This outcome exemplifies our ability to serve sponsors and advance their studies under a variety of circumstances."

About OCT Clinical Trials

OCT Clinical Trials is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT's experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at www.OCT-ClinicalTrials.com.

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses — Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products — Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, visit www.DrReddys.com

Amaliya Ilyasova
OCT Clinical Trials
+7 981 709 20 60

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.